Lucan · Conditions

Doxycycline post-exposure prophylaxis (STIs)

Australian guidance: ASHM Doxy-PEP Position

1. Definition and epidemiology

Doxycycline post-exposure prophylaxis (Doxy-PEP) is a biomedical STI prevention strategy in which a single 200 mg dose of doxycycline is taken within 72 hours of a condomless sexual encounter to reduce acquisition of syphilis and chlamydia. Australia is experiencing a sustained syphilis epidemic, with notifications rising steeply since the mid-2010s; in 2023 the Australian Government declared a national public health emergency driven by infectious syphilis cases concentrated among gay, bisexual, and other men who have sex with men (MSM) and increasingly in heterosexual populations in regional and remote areas. The strategy targets the highest-burden organisms responsible for this epidemic, namely Treponema pallidum (syphilis) and Chlamydia trachomatis, in populations with the greatest exposure risk.

2. Pathophysiology

Doxycycline is a broad-spectrum tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding reversibly to the 30S ribosomal subunit, blocking aminoacyl-tRNA attachment and thereby halting peptide chain elongation. Both T. pallidum and C. trachomatis are tetracycline-susceptible obligate or near-obligate intracellular pathogens with no intrinsic tetracycline resistance mechanisms in Australian circulating strains. A post-exposure dose creates a brief tissue and mucosal drug concentration that is bacteriostatic against these organisms during the early window before systemic dissemination is established. In contrast, Neisseria gonorrhoeae in Australia carries high rates of tetracycline resistance, meaning doxycycline post-exposure prophylaxis does not confer meaningful gonorrhoea protection in the Australian context. The strategy is not effective against viral pathogens including HIV, so concurrent HIV pre-exposure or post-exposure prophylaxis (PrEP or PEP) must be considered independently when indicated. The pharmacological rationale relies on the narrow post-exposure window before the pathogen migrates beyond the reachable mucosal compartment, which is why the 72-hour timeframe is the operative ceiling.

3. Clinical presentation and diagnostic criteria

Doxy-PEP is a prophylactic intervention rather than a treatment, so its "indication" is risk-based rather than symptom-based. Patients appropriate for Doxy-PEP typically present to sexual health or general practice seeking ongoing risk reduction. Key indicators include: a diagnosis of syphilis within the past 12 months; two or more bacterial STI diagnoses (chlamydia, gonorrhoea, or syphilis) within the past 12 months; ongoing sexual practices conferring elevated STI risk such as multiple partners or condomless anal or oral sex; or a clinical context in which acquisition of chlamydia or syphilis would carry serious downstream consequences, for example a person whose sexual network includes women or people with a uterus who could develop congenital syphilis or chlamydial pelvic inflammatory disease. Current evidence most robustly supports use in cisgender MSM and transgender women. There are no specific examination findings that confirm eligibility; the assessment is a structured sexual history combined with STI testing.

4. Investigations and AU-specific cutoffs

Before initiating Doxy-PEP, a full baseline STI screen is required. This includes syphilis serology (initial CMIA or EIA syphilis antibody test, with reflex TPPA/TPHA and RPR if reactive), gonorrhoea and chlamydia NAAT from all relevant anatomical sites (throat, urine/first-void urine, rectal swab), HIV serology, and hepatitis B and C serology. An RPR titre at baseline serves as a quantitative marker of disease activity; a fourfold rise constitutes evidence of new infection or reactivation. Asymptomatic genital or anal lesions should prompt PCR swab of the lesion in addition to serology, as antibody tests may be negative in very early primary syphilis. Ongoing monitoring while on Doxy-PEP follows a 3-monthly STI and HIV screen schedule, with RPR repeated at the same interval to detect breakthrough syphilis. There is no PBS-subsidised blood test specific to Doxy-PEP monitoring; these are billed under standard Medicare STI items.

5. Management

The recommended regimen per the ASHM Doxy-PEP position is doxycycline 200 mg orally taken within 72 hours of a sexual encounter in which condomless sex occurred, with a maximum of one dose per 24-hour period regardless of the number of exposures. Clinical trials underpinning the consensus statement demonstrate approximately 80% reduction in syphilis and chlamydia incidence in eligible populations. The prescribing framework recommended by ASHM involves four components: individualised risk and benefit assessment using the ASHM decision-making tool (ashm.org.au/doxy-dmt); 3-monthly STI and HIV screening; scheduled review of ongoing need for Doxy-PEP at agreed intervals; and antibiotic stewardship counselling covering the rationale for use, side-effect profile, and the limits of protection. National prescribing guidelines were anticipated for early 2026; until these are formalised, prescribing occurs on a private (non-PBS) script basis via the ASHM interim framework. Clinicians should document the shared decision-making process and ensure the patient understands that Doxy-PEP does not replace condom use, HIV prophylaxis, or regular STI testing. Concurrent syphilis found at baseline should be treated per the ASHM syphilis algorithm: benzathine benzylpenicillin 2.4 MU (1.8 g) intramuscularly as a single dose for primary or secondary syphilis, or three weekly doses for early latent syphilis.

6. Pharmacology and AU PBS notes

Doxycycline belongs to the tetracycline class. Its mechanism of action is inhibition of bacterial protein synthesis via 30S ribosomal subunit binding. The Doxy-PEP dose is 200 mg as a single oral post-exposure dose, taken with food to reduce oesophageal irritation and nausea. Australian brands include Doryx (doxycycline hyclate modified release, 200 mg tablet) and Doxsig, as well as multiple generic doxycycline monohydrate and hyclate formulations. The standard 100 mg capsule formulation is widely available; two capsules constitute the 200 mg Doxy-PEP dose.

Doxycycline is not PBS-listed for the Doxy-PEP indication; it is prescribed as a private script. The cost to the patient is typically low given the widespread generic availability of doxycycline 100 mg capsules. Clinicians should note that standard doxycycline listed on the PBS for other indications (acne, malaria prophylaxis) cannot be claimed under those PBS stream codes for this indication. No streamlined authority code applies to Doxy-PEP as of June 2026. Contraindications include known hypersensitivity to tetracyclines, pregnancy (category D, risk of foetal dental and bone toxicity), and concurrent use of retinoids. Doxycycline reduces the efficacy of concurrent oral contraceptives, so patients should be counselled regarding additional contraceptive precautions during and briefly after use.

7. Complications and monitoring

Common adverse effects include nausea, oesophageal irritation, and photosensitisation; patients should be advised to take doses with adequate fluid and food and to use sunscreen. Tetracyclines cause dental discolouration and impaired bone formation in foetal tissue, which is the basis of the absolute contraindication in pregnancy and breastfeeding. The principal longer-term concern is antimicrobial stewardship: population-level Doxy-PEP use carries theoretical risk of selecting for doxycycline resistance in commensal organisms (notably Staphylococcus aureus and gut flora) and could theoretically accelerate resistance in gonorrhoea, where resistance is already prevalent in Australia. Surveillance programs should therefore monitor resistance trends in N. gonorrhoeae and S. aureus in cohorts receiving Doxy-PEP. Breakthrough bacterial STI acquisition despite adherent use warrants genotyping of the infecting strain to detect emerging resistance. Monitoring schedule while on Doxy-PEP: STI screen including RPR, HIV, gonorrhoea and chlamydia NAAT from all sites every 3 months; hepatitis B and C serology at baseline and then as clinically indicated; review of ongoing need and antibiotic stewardship assessment at each 3-month visit; assessment for adverse effects at each visit.

Written for Australian practice and grounded in the guidance named above. Study material only — not medical advice. Always check against current guidelines.